US 10322124
6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases
granted A61KA61K31/353A61K31/355
Quick answer
US patent 10322124 (6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases) held by Sulfateq B.V. expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Sulfateq B.V.
- Grant date
- Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K31/353, A61K31/355, A61K31/4025, A61K31/453